This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
Administration and Storage Choosing ReFacto AFChoosing ReFacto AFChoosing ReFacto AFPersonalised dosing On-Demand Use

Menu

Close

Product InformationProduct InformationLaboratory StandardEfficacy & SafetyAdministration & StorageSupport & ResourcesSupport & ResourcesMaterialsVideosOrdering ReFacto AFContact Us

For ReFacto AF® (moroctocog alfa) Prescribing Information for Great Britain and Northern Ireland click here.
Adverse event reporting information can be found at the bottom of the page.

SHLs: Regular dosing for improved peak controlSHLs: Regular dosing for improved peak controlPersonalised Dosing 

ReFacto AF® offers frequent, flexible dosing so your patients are covered for everyday life. Dose and dose intervals should be based on patients' bleeding profile.1

Dosing with Refacto AF

R2 DeviceReFacto AF® powder and solvent for solution for injection is available in 250 IU, 500 IU, 1000 IU, 2000 IU.2

 

FuseNGoReFacto AF® powder and solvent for solution for injection in a pre-filled syringe is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU.3

 

This image shows the R2 device colour-coded packaging. Each colour corresponds to a different vial dose, making it easier to identify.

Explore more Choosing ReFacto AF®

Find out more about choosing ReFacto AF®: why and the commitment Pfizer has towards haemophilia care.

Find out moreLoading Laboratory Standard 

Find out more about the use of Laboratory Standards and patient satisfaction with the ReFacto AF® FuseNGo device.

 Find out moreLoading Contact us

Contact us for more information on ReFacto AF® and download our FAQ for supply and stock related queries.

 Find out moreLoading

References

ReFacto AF® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.Refacto AF Patient Information Leaflet Refacto AF Patient Information Leaflet for injection in pre-filled syringe.
PP-REF-GBR-0359 July 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​